{"pageContent": "The incidence of prostate cancer is increasing and the patients are generally of relatively advanced age. There has been an increase in the use of hormonal therapy in such cases. However, hormonal therapy for prostate cancer increases the risk of fracture. Bisphosphonates have been reported to prevent the bone loss caused by hormonal therapy. Therefore, oral bisphosphonates will play an important role in preventing bone loss in prostate cancer patients undergoing hormonal therapy.", "metaData": {"source": "Factors influencing men undertaking active surveillance for the management of low-risk prostate cancer\nhttps://pubmed.ncbi.nlm.nih.gov/19136342/"}}